M3 muscarinic receptor Inhibitors
3 drugsAbout M3 muscarinic receptor
The M3 muscarinic receptor is a G protein-coupled receptor activated by acetylcholine, mediating smooth muscle contraction and glandular secretions. As a key member of the muscarinic acetylcholine receptor family, it initiates intracellular signaling cascades upon activation. This makes it a significant target for drug development.
Currently, there is no genetic evidence directly linking M3 receptor variations to specific diseases. However, its involvement in smooth muscle contraction and glandular secretions makes it relevant to conditions affecting these systems.
Three FDA-approved drugs target the M3 receptor: SPIRIVA, DARIFENACIN, and ANORO ELLIPTA. All three drugs are small molecules, with applications spanning respiratory diseases (2 drugs) and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M3 muscarinic receptor Drugs
The competitive landscape includes three companies with approved drugs: MACLEODS PHARMS LTD, GSK, and Boehringer Ingelheim.
Low market concentration suggests moderate entry barriers, but established players have a strong foothold.
M3 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
M3 muscarinic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing therapies.
M3 muscarinic receptor Clinical Trials 154 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 17 | 0 | 2 | 100% |
| Phase 2 | 30 | 24 | 4 | 2 | 86% |
| Phase 3 | 53 | 50 | 3 | 0 | 94% |
| Phase 4 | 52 | 44 | 6 | 2 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M3 muscarinic receptor Drug Approval Timeline (2004 - 2017)
The first drug was approved in 2004 (SPIRIVA), with the most recent approval in 2017 (DARIFENACIN), spanning 14 years.
The approval timeline indicates a mature target, suggesting limited whitespace for new M3-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 129 clinical trials targeting M3 muscarinic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities